Concepedia

Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic

Savithri Ramurthy, Benjamin R. Taft, Robert J. Aversa, Paul A. Barsanti, Matthew T. Burger, Yan Lou, Gisele Nishiguchi, Alice Rico, L Setti, Aaron Smith,

Journal of Medicinal Chemistry · 2019 · 40 citations · 19 references

DOIFull text

Open access

Concepts

Abstract

. Due to its excellent properties, it was progressed through toxicology studies and is being tested in phase 1 clinical trials.

References

19

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Paul B. Chapman, Axel Hauschild, Caroline Robert et al. · New England Journal of Medicine · 2011 · 7.7K citations · Full text

, , +9

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Axel Hauschild, Jean‐Jacques Grob, Lev Demidov et al. · The Lancet · 2012 · 3K citations

, , +11

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

Keith T. Flaherty, J. Infante, Adil Daud et al. · New England Journal of Medicine · 2012 · 2.8K citations · Full text

, , +16

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

J.M. Ostrem, Ulf Peters, Martin L. Sos et al. · Nature · 2013 · 2.5K citations · Full text

, , +14

A quantitative analysis of kinase inhibitor selectivity

Mazen W. Karaman, Sanna Herrgård, Daniel K. Treiber et al. · Nature Biotechnology · 2008 · 2.4K citations

, , +13